Table 5.
Pharmacokinetic parameters
| Treatment | Treatment group | AUC0-t (ng∙hr·mL-1) | Tmax (hr) | Cmax (ng∙mL-1) |
|---|---|---|---|---|
| DZP 2.5 mg | EVP-6124 placebo + DZP 2.5 mg | 16.08 ± 6.097 | 3.61 ± 0.989 | 2.237 ± 0.8462 |
| EVP-6124 0.3 mg + DZP 2.5 mg | 13.87 ± 4.740 | 4.50 ± 2.333 | 1.912 ± 0.6547 | |
| EVP-6124 1 mg + DZP 2.5 mg | 13.50 ± 4.782 | 4.72 ± 1.675 | 1.807 ± 0.6085 | |
| EVP-6124 2 mg + DZP 2.5 mg | 14.05 ± 5.035 | 5.17 ± 2.389 | 1.963 ± 0.8078 | |
| DZP 5.0 mg | EVP-6124 placebo + DZP 5 mg | 41.51 ± 21.780 | 4.30 ± 2.359 | 6.035 ± 2.997 |
| EVP-6124 0.3 mg + DZP 5 mg | 45.26 ± 16.280 | 4.13 ± 1.423 | 6.144 ± 2.800 | |
| EVP-6124 1 mg + DZP 5 mg | 37.68 ± 13.740 | 3.90 ± 0.879 | 5.284 ± 1.6190 | |
| EVP-6124 2 mg + DZP 5 mg | 43.52 ± 13.810 | 3.50 ± 0.737 | 5.424 ± 1.5420 | |
| EVP-6124 0.3 mg | DZP placebo + EVP-6124 0.3 mg | 2474 ± 572.4 | 5.82 ± 0.939 | 281.2 ± 70.48 |
| DZP 2.5 mg + EVP-6124 0.3 mg | 1781 ± 347.2 | 5.81 ± 1.008 | 205.0 ± 39.21 | |
| DZP 5 mg + EVP-6124 0.3 mg | 2176 ± 723.0 | 5.79 ± 0.88 | 249.6 ± 81.94 | |
| EVP-6124 1 mg | DZP placebo + EVP-6124 1 mg | 7412 ± 1379.0 | 5.61 ± 0.672 | 852.6 ± 153.50 |
| DZP 2.5 mg + EVP-6124 1 mg | 5760 ± 1296.0 | 6.88 ± 1.789 | 659.9 ± 140.60 | |
| DZP 5 mg + EVP-6124 1 mg | 6496 ± 1907.0 | 5.71 ± 1.270 | 773.5 ± 198.80 | |
| EVP-6124 2 mg | DZP placebo + EVP-6124 2 mg | 14,600 ± 3310.0 | 5.49 ± 0.911 | 1671.0 ± 360.20 |
| DZP 2.5 mg + EVP-6124 2 mg | 11,220 ± 2002.0 | 5.92 ± 1.35 | 1402.0 ± 252.70 | |
| DZP 5 mg + EVP-6124 2 mg | 12,920 ± 4474.0 | 6.25 ± 1.919 | 1493.0 ± 447.10 | |
| EVP-6124 4 mg | DZP placebo + EVP-6124 4 mg | 27,960 ± 5020.0 | 5.99 ± 1.122 | 3249.00 ± 680.200 |
NOTE. Means ± SD are presented.
Abbreviation: DZP, donepezil.